不油腻的哒哒哒
2022-04-07
failure is the mother of success
Aptinyx slides as diabetic pain trial fails to reach main goal
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":619521606,"tweetId":"619521606","gmtCreate":1649341811621,"gmtModify":1649341811621,"author":{"id":4094711751257690,"idStr":"4094711751257690","authorId":4094711751257690,"authorIdStr":"4094711751257690","name":"不油腻的哒哒哒","avatar":"https://static.tigerbbs.com/521e89acc5ee91cd53fceb36809286c3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>failure is the mother of success</p></body></html>","htmlText":"<html><head></head><body><p>failure is the mother of success</p></body></html>","text":"failure is the mother of success","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/619521606","repostId":2225263513,"repostType":2,"repost":{"id":"2225263513","pubTimestamp":1649338269,"share":"https://www.laohu8.com/m/news/2225263513?lang=&edition=full","pubTime":"2022-04-07 21:31","market":"us","language":"en","title":"Aptinyx slides as diabetic pain trial fails to reach main goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2225263513","media":"seekingalpha","summary":"syahrir maulana/iStock via Getty Images The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX","content":"<html><body><p><figure> <picture> <img src=\"https://media.gettyimages.com/photos/diabetic-neuropathy-text-on-sticky-notes-with-office-desk-concept-picture-id1282091481?b=1&k=20&m=1282091481&s=170667a&w=0&h=8-hdaA47vKiB4O_09z6qoNYLdrVgKkkqD5K6qw9J5jA=\"/> </picture> <figcaption><p>syahrir maulana/iStock via Getty Images</p></figcaption> </figure></p> <ul> <li>The shares of clinical-stage biotech, Aptinyx (<span>NASDAQ:APTX</span>) have <span>lost ~53%</span> in the<span> pre-market Thursday after the company announced that its Phase 2b clinical study for NYX-2925 did not reach the primary endpoint in patients with painful diabetic peripheral neuropathy (DPN).</span> </li> <li>The 229-patient randomized, double-blind study did not demonstrate a statistically significant separation from placebo in terms of its primary endpoint, which was the change in pain from baseline measured over 12 weeks using a rating scale, the company said.</li> <li>“We are clearly disappointed that the study did not meet its primary endpoint,” Chief Executive Andy Kidd remarked, adding, “unfortunately, the data from this study do not currently point to a path forward in development for painful DPN.”</li> <li>However, the experimental therapy was well tolerated in the trial with no “concerning safety issues.” according to Aptinyx (APTX).</li> <li>NYX-2925 is currently undergoing a Phase 2b study for fibromyalgia, with data expected in mid-3Q 2022, the company said. </li> </ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptinyx slides as diabetic pain trial fails to reach main goal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptinyx slides as diabetic pain trial fails to reach main goal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-07 21:31 GMT+8 <a href=https://seekingalpha.com/news/3821627-aptx-stock-slides-as-diabetic-pain-trial-fails-to-reach-main-goal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>syahrir maulana/iStock via Getty Images The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX) have lost ~53% in the pre-market Thursday after the company announced that its Phase 2b clinical ...</p>\n\n<a href=\"https://seekingalpha.com/news/3821627-aptx-stock-slides-as-diabetic-pain-trial-fails-to-reach-main-goal\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"APTX":"Aptinyx Inc.","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3821627-aptx-stock-slides-as-diabetic-pain-trial-fails-to-reach-main-goal","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2225263513","content_text":"syahrir maulana/iStock via Getty Images The shares of clinical-stage biotech, Aptinyx (NASDAQ:APTX) have lost ~53% in the pre-market Thursday after the company announced that its Phase 2b clinical study for NYX-2925 did not reach the primary endpoint in patients with painful diabetic peripheral neuropathy (DPN). The 229-patient randomized, double-blind study did not demonstrate a statistically significant separation from placebo in terms of its primary endpoint, which was the change in pain from baseline measured over 12 weeks using a rating scale, the company said. “We are clearly disappointed that the study did not meet its primary endpoint,” Chief Executive Andy Kidd remarked, adding, “unfortunately, the data from this study do not currently point to a path forward in development for painful DPN.” However, the experimental therapy was well tolerated in the trial with no “concerning safety issues.” according to Aptinyx (APTX). NYX-2925 is currently undergoing a Phase 2b study for fibromyalgia, with data expected in mid-3Q 2022, the company said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":565,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/619521606"}
精彩评论